Wuxi Further Pharmaceutical co., Ltd

Further Pharmaceutical Co.,Ltd (www.further-pharm.com) is an innovation-driven and service-oriented biopharmaceutical company with global operations that develops and manufactures specialty and generic drugs, pharmaceutical intermediates and APIs. Subsidiary companies include Jiangsu Further Pharmaceutical Co.,Ltd, Wuxi Further Pharmaceutical Co.,Ltd, and Canada Further Pharma Inc. Wuxi Further Pharmaceutical Co.,Ltd was founded in 2016 with mission to create highest quality of glocal research & development, manufacturing and marketing chain for small molecule and biologics innovative and generic drugs as well as pharmaceutical intermediates, APIs, and macromolecule polymers/biomaterials with our own IP and innovative drug delivery/formulation technologies. Wuxi R&D center has generic drugs bioequivalence evaluation platform, medicinal chemistry platform, impurities directional preparation technology platform, innovative formulation platform, analytical technology platform, as well as clinical research platform. Canada Further Pharma Inc. is located in Toronto with main focus of medical / pharmaceutical information and regulatory consulting, API DMF application, drug products clinical development and IND/NDA submission, partnership to China FDA registration, licensing and Marketing. Further Pharmaceutical Corporate Value: Integrity, Innovation, Impassioned. Our business covers: - API / Pharmaceutical Intermediates / Nutritional supplements raw material selling Main Products: - Voglibose & Intermediates - Crizotinib & Intermediates - Uracil - Folic Acid & Intermediates - Methyl syringate - Finished Dosage - Analysis and Detection - Clinical Research - Registration Declaration - Innovative drugs - Consistency Evaluation Email: susie@further-pharm.com Phone: +86 18036885286